FR2657259B1 - - Google Patents

Info

Publication number
FR2657259B1
FR2657259B1 FR9000834A FR9000834A FR2657259B1 FR 2657259 B1 FR2657259 B1 FR 2657259B1 FR 9000834 A FR9000834 A FR 9000834A FR 9000834 A FR9000834 A FR 9000834A FR 2657259 B1 FR2657259 B1 FR 2657259B1
Authority
FR
France
Prior art keywords
myristoyl
phenylalanine
aids
cancer
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9000834A
Other languages
English (en)
French (fr)
Other versions
FR2657259A1 (fr
Inventor
Michel Vincent
Georges Remond
Yolande Herve
Jean-Albert Boutin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ADIR SARL
Original Assignee
ADIR SARL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ADIR SARL filed Critical ADIR SARL
Priority to FR9000834A priority Critical patent/FR2657259A1/fr
Priority to JP3007188A priority patent/JPH0717503B2/ja
Priority to CA002034861A priority patent/CA2034861A1/fr
Priority to US07/645,124 priority patent/US5164414A/en
Priority to IE24291A priority patent/IE65573B1/en
Priority to PT96571A priority patent/PT96571A/pt
Priority to ES91400163T priority patent/ES2060310T3/es
Priority to AT91400163T priority patent/ATE94387T1/de
Priority to AU69987/91A priority patent/AU633395B2/en
Priority to OA59940A priority patent/OA09478A/xx
Priority to DE91400163T priority patent/DE69100364T2/de
Priority to DK91400163.1T priority patent/DK0443891T3/da
Priority to ZA91574A priority patent/ZA91574B/xx
Priority to EP91400163A priority patent/EP0443891B1/fr
Publication of FR2657259A1 publication Critical patent/FR2657259A1/fr
Application granted granted Critical
Publication of FR2657259B1 publication Critical patent/FR2657259B1/fr
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FR9000834A 1990-01-25 1990-01-25 Utilisation de la n-myristoyl-(s)-phenylalanine pour l'obtention de medicaments destines au traitement des maladies faisant intervenir la myristoylation. Granted FR2657259A1 (fr)

Priority Applications (14)

Application Number Priority Date Filing Date Title
FR9000834A FR2657259A1 (fr) 1990-01-25 1990-01-25 Utilisation de la n-myristoyl-(s)-phenylalanine pour l'obtention de medicaments destines au traitement des maladies faisant intervenir la myristoylation.
CA002034861A CA2034861A1 (fr) 1990-01-25 1991-01-24 Utilisation de la n-myristoyl-(s)-phenylalanine pour l'obtention de medicaments destines au traitement des maladies faisant intervenir la myristoylation
US07/645,124 US5164414A (en) 1990-01-25 1991-01-24 Use of n-myristoyl-(s)-phenylalanine for the treatment of diseases involving myristoylation
IE24291A IE65573B1 (en) 1990-01-25 1991-01-24 Use of N-myristoyl-(S)-phenylalanine for obtaining medicinal products intended for the treatment of diseases involving myristoylation
PT96571A PT96571A (pt) 1990-01-25 1991-01-24 Processo para a preparacao de composicoes farmaceuticas contendo n-miristoil-(s)-fenilalanina
JP3007188A JPH0717503B2 (ja) 1990-01-25 1991-01-24 ミリストイル化を伴う疾患の治療を意図する薬効のある生成物を得るためのｎ−ミリストイル−（ｓ）−フェニルアラニンの使用
ES91400163T ES2060310T3 (es) 1990-01-25 1991-01-25 Utilizacion de la n-miristoil-(s)-fenilalanina para la obtencion de medicamentos destinados al tratamiento de enfermedades que hacen intervenir la miristoilacion.
AT91400163T ATE94387T1 (de) 1990-01-25 1991-01-25 Verwendung von n-myristoyl-(s)-phenylalanin zur herstellung eines medikaments zur behandlung von krankheiten mittels hemmung der myristoylierung.
AU69987/91A AU633395B2 (en) 1990-01-25 1991-01-25 Use of n-myristoyl-(s)-phenylalanine for obtaining medicinal products intended for the treatment of diseases involving myristoylation
OA59940A OA09478A (fr) 1990-01-25 1991-01-25 "Utilisation de la N-myristoyl-(S)-phénylalaine pour l'obtention de médicaments destinés au traitement des maladies faisant intervenir la myristoylation".
DE91400163T DE69100364T2 (de) 1990-01-25 1991-01-25 Verwendung von N-Myristoyl-(S)-Phenylalanin zur Herstellung eines Medikaments zur Behandlung von Krankheiten mittels Hemmung der Myristoylierung.
DK91400163.1T DK0443891T3 (da) 1990-01-25 1991-01-25 Anvendelse af N-myristotyl-(S)-phenylalanin eller et additionssalt deraf med en farmaceutisk acceptabel base til opnåelse af et farmaceutisk middel og farmaceutisk middel til behandling af sygdomme ved indgribning i myristoyleringen
ZA91574A ZA91574B (en) 1990-01-25 1991-01-25 Use of n-myristoyl-(s)-phenylalanine for obtaining medicinal products for the treatment of diseases involving myristoylation
EP91400163A EP0443891B1 (fr) 1990-01-25 1991-01-25 Utilisation de la N-myristoyl-(S)-phénylalanine pour l'obtention de médicaments destinés au traitement des maladies faisant intervenir la myristoylation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9000834A FR2657259A1 (fr) 1990-01-25 1990-01-25 Utilisation de la n-myristoyl-(s)-phenylalanine pour l'obtention de medicaments destines au traitement des maladies faisant intervenir la myristoylation.

Publications (2)

Publication Number Publication Date
FR2657259A1 FR2657259A1 (fr) 1991-07-26
FR2657259B1 true FR2657259B1 (show.php) 1994-08-19

Family

ID=9393082

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9000834A Granted FR2657259A1 (fr) 1990-01-25 1990-01-25 Utilisation de la n-myristoyl-(s)-phenylalanine pour l'obtention de medicaments destines au traitement des maladies faisant intervenir la myristoylation.

Country Status (14)

Country Link
US (1) US5164414A (show.php)
EP (1) EP0443891B1 (show.php)
JP (1) JPH0717503B2 (show.php)
AT (1) ATE94387T1 (show.php)
AU (1) AU633395B2 (show.php)
CA (1) CA2034861A1 (show.php)
DE (1) DE69100364T2 (show.php)
DK (1) DK0443891T3 (show.php)
ES (1) ES2060310T3 (show.php)
FR (1) FR2657259A1 (show.php)
IE (1) IE65573B1 (show.php)
OA (1) OA09478A (show.php)
PT (1) PT96571A (show.php)
ZA (1) ZA91574B (show.php)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2672598A1 (fr) * 1991-02-11 1992-08-14 Adir Nouveaux inhibiteurs de n-myristoyltransferase, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5859052A (en) * 1993-01-14 1999-01-12 G. D. Searle & Co. Fatty acid analogs and prodrugs
US5599947A (en) * 1993-01-14 1997-02-04 G. D. Searle & Co. Fatty acid analogs and prodrugs
US6407125B1 (en) 1995-12-29 2002-06-18 Novactyl, Inc. Pharmacological agent and method of treatment
US6127393A (en) * 1995-12-29 2000-10-03 Novactyl, Inc. Antiproliferative, antiinfective, antiinflammatory, autologous immunization agent and method
US6579891B1 (en) 1995-12-29 2003-06-17 Novactyl, Inc. Agent and method for prevention and treatment of cancer in animals
US6743771B2 (en) 1995-12-29 2004-06-01 Novactyl, Inc. Methods and compositions for controlling protein assembly or aggregation
US6441009B1 (en) 1998-08-01 2002-08-27 Novactyl, Inc. Agent and method of preventing and treating heavy metal exposure and toxicity
CA2388754C (en) * 1999-10-13 2010-07-13 Marco A. Chacon Therapeutic intervention to mimic the effect of caloric restriction
US6403618B1 (en) 2000-02-15 2002-06-11 Novactyl, Inc. Agent and method for controlling angiogenesis
AU2002318427A1 (en) * 2001-06-25 2003-03-03 University Of Massachusetts N-fatty acid-amino acid conjugates and therapeutic uses
DE10353806A1 (de) * 2003-11-14 2005-07-07 Bundesrepublik Deutschland, vertreten durch das Bundesministerium für Gesundheit, dieses vertreten durch das Robert-Koch-Institut, vertreten durch seinen Präsidenten Verwendung von Aminosäure- und Zucker-Amphiphilen zur Inaktivierung von lipidumhüllten Viren
US7544714B2 (en) * 2004-07-16 2009-06-09 University Of Massachusetts Lipid-amino acid conjugates and methods of use
IL172896A0 (en) * 2005-12-29 2006-06-11 Yeda Res & Dev Cxcr4 inhibition
ES2937269T3 (es) 2011-07-22 2023-03-27 Pacylex Pharmaceuticals Inc Letalidad sintética y el tratamiento del cáncer
EP2830437B1 (en) 2012-03-30 2018-12-26 Givaudan SA N-acylated 1-aminocycloalkyl carboxylic acids as food flavouring compounds
JP6224072B2 (ja) 2012-03-30 2017-11-01 ジボダン エス エー フレーバープロフィール食用組成物の改良のためのｎ−アシル−アミノ酸誘導体
US10711230B2 (en) 2012-03-30 2020-07-14 Givaudan Sa N-acyl proline derivatives as food flavoring compounds
BR112014023905B1 (pt) 2012-03-30 2021-07-13 Givaudan Sa Composições de sabor e comestíveis compreendendo derivados de metionina n-acilados e bebida calórica e não-calórica
WO2013148991A1 (en) 2012-03-30 2013-10-03 Givaudan S.A. N-acyl derivatives of gamma amino - butyric acid and and beta alanine as food flavouring compounds
US10836712B2 (en) 2012-03-30 2020-11-17 Givaudan S.A. Organic compounds
US10582715B2 (en) 2012-03-30 2020-03-10 Givaudan Sa Powder flavour composition
CA2890113C (en) * 2012-10-30 2023-01-17 Pacylex Pharmaceuticals Inc. Synthetic lethality and the treatment of cancer
WO2015050535A1 (en) 2013-10-02 2015-04-09 Givaudan S.A. Organic compounds
EP3052472B1 (en) 2013-10-02 2019-02-27 Givaudan S.A. N-acylated 2-aminoisobutyric acid compounds and flavour compositions containing them
US10674755B2 (en) 2013-10-02 2020-06-09 Givaudan S.A. Organic Compounds
WO2015048990A1 (en) 2013-10-02 2015-04-09 Givaudan Sa Organic compounds having taste-modifying properties
US10834950B2 (en) 2013-10-02 2020-11-17 Givaudan S.A. Organic compounds
WO2015048991A1 (en) 2013-10-02 2015-04-09 Givaudan Sa Organic compounds having taste-modifying properties
US10537127B2 (en) 2013-10-02 2020-01-21 Givaudan S.A. Organic compounds
GB201317424D0 (en) 2013-10-02 2013-11-13 Givaudan Sa Improvements in or relating to organic compounds
EP3325662B1 (en) 2015-07-17 2023-08-30 Pacylex Pharmaceuticals Inc. Epigenetic silencing of nmt2

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4778878A (en) * 1986-08-07 1988-10-18 Washington University Novel inhibitor peptides I
US4778877A (en) * 1986-08-07 1988-10-18 Washington University Novel inhibitor peptides II

Also Published As

Publication number Publication date
DE69100364T2 (de) 1994-04-21
ATE94387T1 (de) 1993-10-15
US5164414A (en) 1992-11-17
EP0443891B1 (fr) 1993-09-15
OA09478A (fr) 1992-11-15
ES2060310T3 (es) 1994-11-16
PT96571A (pt) 1991-10-15
AU6998791A (en) 1991-08-01
IE65573B1 (en) 1995-11-01
AU633395B2 (en) 1993-01-28
DK0443891T3 (da) 1993-12-27
ZA91574B (en) 1991-11-27
FR2657259A1 (fr) 1991-07-26
DE69100364D1 (de) 1993-10-21
JPH0717503B2 (ja) 1995-03-01
IE910242A1 (en) 1991-07-31
CA2034861A1 (fr) 1991-07-26
EP0443891A1 (fr) 1991-08-28
JPH04210916A (ja) 1992-08-03

Similar Documents

Publication Publication Date Title
FR2657259B1 (show.php)
AU1808488A (en) Compounds for the treatment of alzheimer's disease
NL300433I1 (en) Methods and compositions for the treatment of glomerulonephritis
BR9102126A (pt) Composicao de tratamento de tecido
EP0499467A3 (en) Use of quinones in the treatment of cancer or aids
ZA973622B (en) Use of forms of hyaluronic acid (HA) for the treatment of cancer.
IL99778A0 (en) Compositions for the treatment of cell proliferation disorders
NO913117L (no) Fremgangsmaate for behandling av benoedeleggende sykdommer.
ZA929879B (en) Compositions for the treatment of mammalian diseases.
DE3462688D1 (en) 1,7-diphenyl-3-methylaza-7-cyano-8-methylnonane useful in combating diseases
ZA914435B (en) Treatment of disease
GB9024860D0 (en) Treatment of dispersions
ZA908490B (en) Use of arylalkylamides in the treatment of neurodegenerative diseases
IL89901A0 (en) Strobilurine derivatives
IE900460L (en) Pharmaceutical composition
GB9026737D0 (en) Cancer treatment
LV10385B (en) Use of quinons in the treatment of cancer or aids
GB2266242A (en) Feet deodorising agents
ES1022564Y (es) Armonizador electromagnetico de las alteraciones fisiologicas del cuerpo humano.
GB9008524D0 (en) Treatment of cancer
PT94432A (pt) Processo para a producao sulfonamidas substituidas e compostos afins uteis no tratamento da asma, artrite e doencas afins
GR900100297A (en) Cylinder for the treatment of furs
GB9024140D0 (en) Medical treatment
GB9026067D0 (en) Medical treatment
GB9014890D0 (en) Improvements in the treatment of animal feeds

Legal Events

Date Code Title Description
ST Notification of lapse